The Kidney Cancer Program seeks to conduct innovative basic research into the molecular and biological basis for various cancers of the kidney with the goals of identifying: 1) meaningful biomarkers for eariy detection, prognosis and treatment selection;2) novel factors associated with either innate or acquired resistance to existing therapies that could be targets for future therapeutic development;and 3) new therapeutic targets. In addition, the Program seeks to conduct cutting-edge clinical trials across all disease strata in the hopes of identifying more effective treatments, used either alone or in combination, and better ways of predicting who should receive each therapy. It also aims to better understand the factors contribufing to kidney cancer development and the relative cost effectiveness of various diagnosfic and treatment approaches. Finally, the Kidney Cancer Program will to continue to educate, train and promote the career advancement of the next generation of kidney cancer investigators. The Program has five Specific Aims: 1. idenfify and validate novel targets for renal cell carcinoma (RCC) and other cancers of the kidney 2. Identify biomarkers for eariy detection, prognosis and treatment selection 3. Identity mechanisms for and opportunities for overcoming resistance to existing RCC therapies 4. Explore novel immunotherapies, either alone of in combination, in patients with advanced RCC 5. Investigate the epidemiology of RCC and cost effectiveness of treatment for this disease. The Program was first approved and funded by the NCI CCSG in 2005, at which fime it received a score of "Excellent to Outstanding" merit. The Program has 36 members from six DF/HCC institutions, seven departments of HMS and one department of HSPH. In 2009, total peer-review funding totaled $3.8 million (total costs), of which $3 million was from the NCI. During the project period (2006 to 2010), members published 371 papers, of which 15% were intra-programmafic , 41% were inter-programmatic and 27% were inter-institufional.
Cancers of the kidney are the second most common cancer of the genitourinary tract with over 50,000 new cases diagnosed annually accounting forever 13,000 deaths. This program seeks to understand the molecular basis for various cancers of the kidney in order to enhance early detection and treatment selection and devise better therapies that together can reduce the pain and suffering related to these cancers.
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications